UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-41925 CG Oncology, Inc. Indicate by check mark whether the registrant (1) has fil ...

CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.3 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.49 per share when it actually produced a loss of $0.54, delivering a surprise of -10.2%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.CG Oncology, Inc., which belongs ...

Exhibit 99.1 CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates IRVINE, Calif., November 14, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the third quarter ended September 30, 2025, and provided business updates. "I am proud of the meaningful progress ...

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated continued best-in-disease durability and tolerability in BOND-003 Cohort C with robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with HR NMIBC unresponsive to Bacillus Calmette Guerin (BCG)Completed enrollment of PIVOT-006, one of the largest randomized Phas ...

CG Oncology, Inc. (NASDAQ:CGON) is one of the best healthcare stocks with the highest upside. On October 7, CG Oncology, Inc. (NASDAQ:CGON) was initiated with a Buy rating by Guggenheim analyst Brad Canino, who assigned the stock a $90 price target. Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? The firm told investors in a research note that it sees the company “rising to the top of quality oncology ideas.” It added that the non-muscle invasive bladder cancer marke ...

公司概况与投资评级 - CG Oncology Inc (NASDAQ:CGON) 是一家后期临床生物制药公司 专注于为膀胱癌患者开发和商业化保留膀胱的骨干疗法 [4] - Guggenheim分析师Brad Canino首次覆盖公司 给予买入评级和90美元的目标价 [1] 核心产品管线与适应症 - 公司核心在研产品为cretostimogene grenadenorepvec 一种研究性溶瘤免疫疗法 作为非肌层浸润性膀胱癌的潜在保留膀胱治疗方案 [2] - 该产品针对的非肌层浸润性膀胱癌市场拥有大量患者且具备定价能力 [1] 临床试验进展与监管路径 - 公司已启动CORE-008 Cohort CX试验 评估cretostimogene与吉西他滨联合用于高危非肌层浸润性膀胱癌患者 [3] - PIVOT-006试验的3期患者入组预计在第三季度完成 [3] - 针对cretostimogene的生物制剂许可申请提交计划在第四季度启动 预计将于2026年进入FDA审评阶段 [1][3]

生物技术板块盘后表现 - 多家生物技术公司股票在10月9日周四盘后交易中出现显著上涨，受新数据、战略更新和公司发展消息推动 [1] Palisade Bio Inc (PALI) - 公司股票在10月9日晚上9:16 EDT盘后交易中报2.26美元，较前收盘价上涨7.62%，当日常规交易时段收于2.10美元，上涨5% [1] - 公司取消了原定于10月10日重新召开的特殊股东会议，原因是持续缺乏法定人数，因此撤回了于2025年8月18日提交的最终代理声明中的所有提案 [2] - 公司股票过去52周交易区间为0.53美元至4.32美元 [1] Healthcare Triangle Inc (HCTI) - 公司股票在10月9日晚上7:58:50 EDT盘后交易中报2.88美元，上涨4.35%，当日常规交易时段收于2.76美元，下跌17.86% [3] - 公司签署不具约束力的意向书，计划收购Teyame.AI，该收购预计将为2025财年带来3400万美元收入，并为公司提供新一代全球客户互动平台 [4] - 公司股票过去52周交易区间为1.49美元至473.10美元 [3] Nutriband Inc (NTRB) - 公司股票在10月9日晚上6:24 EDT盘后交易中报8.25美元，上涨4.30%，当日常规交易时段收于7.91美元，下跌6.94% [5] - 公司已向美国专利商标局提交临时专利申请，以进一步加强其AVERSA防滥用透皮技术的知识产权保护 [5] - 公司股票过去52周交易区间为3.72美元至11.78美元 [5] Karyopharm Therapeutics Inc (KPTI) - 公司股票在10月9日晚上7:37 EDT盘后交易中报6.08美元，较常规交易时段收盘价5.82美元上涨4.46%，当日常规时段股价下跌1.36% [6] - 公司宣布了全面的融资和资本结构交易，预计将提供1亿美元的财务灵活性，并将其现金跑道延长至2026年第二季度 [6] - 公司股票过去52周交易区间为3.51美元至16.95美元 [6] Editas Medicine Inc (EDIT) - 公司股票在10月9日晚上7:59 EDT盘后交易中报4.22美元，上涨3.43%，当日常规交易时段收于4.08美元，下跌1.69% [7] - 公司在欧洲基因与细胞治疗学会大会上公布了其实验性疗法EDIT-401的新临床前概念验证数据，显示在非人灵长类动物和小鼠中可实现90%的LDL-C降低 [7] - 公司股票过去52周交易区间为0.91美元至4.54美元 [7] CG Oncology Inc (CGON) - 公司股票在10月9日晚上7:59:45 EDT盘后交易中报45.40美元，上涨2.11%，当日常规交易时段收于44.46美元，上涨9.21% [8] - 当日未发布官方新闻稿或文件 [8] - 公司股票过去52周交易区间为14.80美元至45.47美元 [8]

In my last coverage of CG Oncology, Inc. (NASDAQ: CGON ), I had a shift in sentiment from "Hold" to "Buy" based on key catalysts that we could look forward to in 2025. Since then, theI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analys ...

One pundit believes this is a clinical-stage company well worth watching.Highly specialized biotech CG Oncology (CGON 7.13%) was the subject of a new research report Wednesday, and its bullish tone helped lift the company's share price. This improved by more than 7% on the day, easily beating the 0.6% advance of the bellwether S&P 500 (^GSPC 0.58%). A biotech with a tight focusThat publication marked the initiation of coverage on CG Oncology stock by veteran researcher Guggenheim, in the person of prognosti ...

CG Oncology Inc. (NASDAQ:CGON) is one of the best new stocks to buy right now. On September 17, Morgan Stanley raised the firm’s price target on CG Oncology to $79 from $56, while maintaining an Overweight rating on the shares. Earlier in August, CG Oncology announced significant clinical advancements in its bladder cancer pipeline and financial results for Q2 2025. The company is focused on developing cretostimogene grenadenorepvec, which is an investigational oncolytic immunotherapy for Non-Muscle Invas ...